Dako to Collaborate with Pfizer on Companion Diagnostics
(Thomson Reuters ONE) -
GLOSTRUP, Denmark, Feb. 12, 2013 - Dako, an Agilent Technologies company,
announced today it has entered into a collaboration agreement with Pfizer in the
field of companion diagnostics.
The agreement constitutes a legal framework for various collaboration projects
between the two companies, covering research, development and commercialization
as well as advisory services.
"We are extremely excited to partner with Pfizer, a company with such a global
presence and reputation for market leadership," said Lars Holmkvist, CEO of Dako
and senior vice president, Agilent. "This collaboration is testimony to the
level of expertise and service Dako is committed to delivering to our partners
in companion diagnostics."
Companion diagnostics are seen as the cornerstones of precision medicine. They
provide a way to improve patient care and reduce health-care costs by matching
specific therapies to the individuals most likely to benefit from them, since
all patients do not respond in the same way.
"This partnership with Dako will support Pfizer's companion diagnostics efforts,
an important component of our growing Precision Medicine capabilities," said
John Hubbard, senior vice president, Development Operations at Pfizer.
"Precision Medicine R&D is designed to advance more targeted therapies for
patients, improve efficacy, safety and success rates, and expedite
development."
Financial terms of the agreement were not disclosed.
Today's news follows an earlier announcement from Dako introducing a master
framework agreement between Dako and Eli Lilly and Company, which focuses on
developing novel companion diagnostics for Eli Lilly's oncology pipeline.
About Dako - An Agilent Technologies Company
Dako is relentless in its commitment to fighting cancer together with customers
and strategic partners-because patients' lives depend on companies continuing to
bring scientific advancement to the diagnostic and therapeutic fields.
Dako, based in Denmark, is a global leader in tissue-based cancer diagnostics.
Hospital and research laboratories worldwide use Dako's reagents, instruments,
software and expertise to make accurate diagnoses and determine the most
effective treatment for cancer patients. Dako, with 1,200 employees, operates in
more than 100 countries. Dako became part of Agilent Technologies on June
21, 2012. Information about Dako is available at www.dako.com.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company
and a technology leader in chemical analysis, life sciences, diagnostics,
electronics and communications. The company's 20,500 employees serve customers
in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal
2012. Information about Agilent is available at www.agilent.com.
EDITORIAL CONTACT:
Maia Fredtoft Søchting
Communications
+45 25 46 10 83
Dako Denmark A/S
maia.sochting(at)dako.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Dako Denmark A/S via Thomson Reuters ONE
[HUG#1677383]
Unternehmensinformation / Kurzprofil:
Datum: 12.02.2013 - 17:00 Uhr
Sprache: Deutsch
News-ID 228781
Anzahl Zeichen: 3835
contact information:
Town:
Glostrup
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 237 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Dako to Collaborate with Pfizer on Companion Diagnostics"
steht unter der journalistisch-redaktionellen Verantwortung von
Dako Denmark A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
